Notch signalling: multifaceted role in development and disease
N Sachan, V Sharma, M Mutsuddi… - The FEBS …, 2023 - Wiley Online Library
Notch pathway is an evolutionarily conserved signalling system that operates to influence an
astonishing array of cell fate decisions in different developmental contexts. Notch signalling …
astonishing array of cell fate decisions in different developmental contexts. Notch signalling …
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
Y Kikushige - Journal of clinical and experimental hematopathology, 2020 - jstage.jst.go.jp
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western
countries and is characterized by the clonal expansion of mature CD5+ B cells. There have …
countries and is characterized by the clonal expansion of mature CD5+ B cells. There have …
[HTML][HTML] Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping
K Neveling, T Mantere, S Vermeulen… - The American Journal of …, 2021 - cell.com
Somatic structural variants (SVs) are important drivers of cancer development and
progression. In a diagnostic set-up, especially for hematological malignancies, the …
progression. In a diagnostic set-up, especially for hematological malignancies, the …
Pharmacological disruption of the Notch transcription factor complex
R Lehal, J Zaric, M Vigolo, C Urech… - Proceedings of the …, 2020 - National Acad Sciences
Notch pathway signaling is implicated in several human cancers. Aberrant activation and
mutations of Notch signaling components are linked to tumor initiation, maintenance, and …
mutations of Notch signaling components are linked to tumor initiation, maintenance, and …
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
H Huber, E Tausch, C Schneider, S Edenhofer… - Blood, 2023 - ashpublications.org
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response
and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …
and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …
[HTML][HTML] Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its
indolent clinical course, therapy refractoriness and disease progression still represent an …
indolent clinical course, therapy refractoriness and disease progression still represent an …
[HTML][HTML] Revisiting Richter transformation in the era of novel CLL agents
A Petrackova, P Turcsanyi, T Papajik, E Kriegova - Blood Reviews, 2021 - Elsevier
Richter transformation (RT) is the development of aggressive lymphoma–most frequently
diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL)–arising on the …
diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL)–arising on the …
[HTML][HTML] Richter syndrome: from molecular pathogenesis to druggable targets
S Mouhssine, G Gaidano - Cancers, 2022 - mdpi.com
Simple Summary Chronic lymphocytic leukemia represents the most frequent leukemia in
adults and evolves from an indolent phase to an aggressive lymphoma in 5–10% of the …
adults and evolves from an indolent phase to an aggressive lymphoma in 5–10% of the …
BCOR gene alterations in hematologic diseases
P Sportoletti, D Sorcini, B Falini - Blood, The Journal of the …, 2021 - ashpublications.org
The BCL6 corepressor (BCOR) is a transcription factor involved in the control of
embryogenesis, mesenchymal stem cells function, hematopoiesis, and lymphoid …
embryogenesis, mesenchymal stem cells function, hematopoiesis, and lymphoid …
[HTML][HTML] Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
E Bahrami, JP Schmid, V Jurinovic, M Becker… - Molecular Cancer, 2023 - Springer
Background Acute leukemias represent deadly malignancies that require better treatment.
As a challenge, treatment is counteracted by a microenvironment protecting dormant …
As a challenge, treatment is counteracted by a microenvironment protecting dormant …